GUANGDONG, CHINA AND BAGSVÆRD, DENMARK – Media OutReach Newswire – 24 March 2025 – The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (Novo Nordisk) today announced that ...

Novo will pay Hong Kong-based United Laboratories $200 million upfront for the drug, which combines three different ...

The United Laboratories International Holdings ( ($HK:3933) ) has issued an update. The United Laboratories International Holdings Limited ...

Novo Nordisk A/S agreed to pay United Laboratories International Holdings as much as $2 billion for a next-generation obesity drug, the Danish Ozempic maker’s latest move to refill its pipeline ...

Under terms of the license agreement, Novo Nordisk will acquire the rights to develop and commercialize UBT251 outside of ...

The United Laboratories International Holdings Limited (OTCMKTS:ULIHF – Get Free Report) was the target of a significant growth in short interest during the month of February. As of February 28th, ...

March 24 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO), opens new tab has bought global rights to China-based United Laboratories International's (3933.HK), opens new tab so-called "triple ...

(Reuters) -Danish drugmaker Novo Nordisk has bought global rights to China-based United Laboratories International's so-called "triple-G" weight-loss drug candidate in a deal worth up to $2 billion.